Who are Calquence's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brukinsa, Itovebi, Romvimza, Wayrilz, Hernexeos, LAZERTINIB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acalabrutinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Calquence — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calquence (ACALABRUTINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Tyrosine-protein kinase BTK Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Calquence (ACALABRUTINIB) — AstraZeneca. Calquence works by blocking the activity of the BTK enzyme, which is essential for the activation and survival of B cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Calquence TARGET	ACALABRUTINIB	AstraZeneca	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2017-01-01
Brukinsa	BGB-3111	Beigene Usa Inc	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Itovebi	INAVOLISIB	Genentech Inc	marketed	Kinase Inhibitor [EPC]		2025-01-01
Romvimza	VIMSELTINIB	Deciphera Pharms	marketed	Kinase Inhibitor [EPC]		2025-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01
Hernexeos	ZONGERTINIB	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]		2025-01-01
LAZERTINIB	LAZERTINIB		marketed	Kinase Inhibitor [EPC]		2024-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-04-22 — Brukinsa · 10570139 · US
2034-04-22 — Brukinsa · 11142528 · US
2034-04-22 — Brukinsa · 9447106 · US
2037-08-15 — Brukinsa · 11591340 · US
2037-08-15 — Brukinsa · 10927117 · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Calquence — Competitive Intelligence Brief. https://druglandscape.com/ci/acalabrutinib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing